Overall survival of patients with HER2-negative metastatic breast cancer treated with a first-line paclitaxel with or without bevacizumab in real-life setting: Results of a multicenter national observational study.

Affiliation auteurs!!!! Error affiliation !!!!
TitreOverall survival of patients with HER2-negative metastatic breast cancer treated with a first-line paclitaxel with or without bevacizumab in real-life setting: Results of a multicenter national observational study.
Type de publicationJournal Article
Year of Publication2016
AuteursDelaloge S, Perol D, Brain E, Asselain B, Bachelo TDenis, Debled M, Dieras V, Campone M, Levy C, Jacot W, Lorgis V, Veyret C, Dalenc F, Ferrero J-M, Uwer L, Goncalves A, Piot I, Simon G, Robain M, Cailliot C
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume34
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X
DOI10.1200/JCO.2016.34.15_suppl.1013